Enhertu for Breast Cancer User Reviews
Enhertu has an average rating of 8.3 out of 10 from a total of 3 reviews for the treatment of Breast Cancer. 67% of reviewers reported a positive experience, while 0% reported a negative experience.
- KUMARI
- Taken for 1 to 2 years
- March 30, 2024
"True and Best Injection for HER2-POSITIVE Treatment."
- Jane...
- Taken for 1 to 6 months
- March 19, 2024
"Only 2 infusions, on Zofran and dexamethasone, caused severe constipation and cramps. Tumor markers next, only 2 infusions."
Frequently asked questions
- What is the success rate of Enhertu in metastatic breast cancer?
- Is Enhertu a chemotherapy drug? What's Enhertu used for?
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
Learn more about Breast Cancer
- Breast Cancer Guide
- Breast Cancer: Treatment and Prevention Options
- Cancer Center
- FDA-Approved Weight Loss Drugs: Can They Help You?
Care guides
Symptoms and treatments
Medicine.com guides (external)
More about Enhertu (fam-trastuzumab deruxtecan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (23)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- En español
"It is saving my life & has limited side effects. While I am on it, my tumor did not spread or grow."